LAG-3

[Nature Communications] Investigators used multi-omics single-cell analysis to probe the dynamic immune responses in hospitalized patients with stable or progressive course of COVID-19, explore V(D)J repertoires, and assess the cellular effects of tocilizumab.

[Journal of Immunology] The authors observed significantly fewer LAG-3+ CD4 and CD8 T cells from subjects with relapsing-remitting multiple sclerosis and type 1 diabetes.

[BeiGene] BeiGene announced entry into a license and collaboration agreement granting BeiGene worldwide research, development and manufacturing rights and exclusive commercialization rights outside of China to LBL-007, a novel investigational antibody targeting the LAG-3 pathway.

[Molecular Therapy-Oncolytics] Scientists found that oncolytic adenovirus conferred an effective ability to reduce ascites development and prolong overall survival.

[Advanced Science] Among various cell sources, FGL1/PD-L1 small extracellular vesicles (sEVs) derived from MSCs not only enriched FGL1/PD-L1 expression but also maintained the immunomodulatory properties of unmodified MSC sEVs.

[Galecto, Inc.] Galecto, Inc. announced that it has entered into a clinical trial supply agreement with Roche to explore the combination of GB1211, Galecto’s oral galectin-3 inhibitor, with Roche’s PD-L1 checkpoint inhibitor atezolizumab in Galecto’s planned Phase IIa trial in non-small-cell lung cancer